Regulatory & market landscape
Few investigational drugs are watched as closely as CagriSema, because it sits at the center of a multi-billion-dollar…
A drug the market is watching, not yet selling
Few investigational drugs are watched as closely as CagriSema, because it sits at the center of a multi-billion-dollar obesity market. Yet as of August 2026 it is approved nowhere: a US New Drug Application went in on 18 December 2025 and is still under review, and meanwhile its "research peptide" shadow market is entirely unregulated.
This unit maps the regulatory reality, the market stakes that made a topline number move a stock price, and the athlete and legal considerations that follow from an unapproved metabolic drug.
Key terms
The regulatory status
The headline is simple: cagrilintide and CagriSema are approved nowhere as of August 2026. No FDA, EMA, or Japanese (PMDA) approval exists. Filed is not the same as approved, and CagriSema is now firmly in that gap: Novo Nordisk announced on 18 December 2025 that it had submitted a New Drug Application to the FDA for chronic weight management, on the strength of REDEFINE 1 and REDEFINE 2. The application is under review, and in February 2026 the sponsor said it anticipates an FDA decision by late 2026.
The regulatory picture is coherent: a drug with strong phase 3 data, filed in the United States but not yet approved anywhere. That distinction matters more than it sounds. A filing is a company asking; an approval is a regulator answering. Until the answer comes, nothing about the legal availability of the drug has changed.
AdvancedWhy a filing rests on more than one trial
Regulators evaluate a drug on its full evidence package, not one trial. The sponsor states that the CagriSema weight-management submission rests on the two pivotal trials, REDEFINE 1 (3,417 adults with obesity or overweight and a complication, without diabetes) and REDEFINE 2 (1,206 adults with type 2 diabetes and obesity or overweight), with supporting safety and pharmacology from the wider program including REDEFINE 5 in Japan and Taiwan. Assembling, cleaning, and analyzing that combined dataset is why years separate a topline announcement from a submission.